AstraZeneca and MSD’s Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

According to results from the OlympiA Phase III trial, published in The New England Journal of Medicine and in line for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 6, the drug demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo in the adjuvant treatment setting.

In the overall trial population of patients who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, data showed Lynparza cut the risk of invasive breast cancer recurrences, second cancers or death by 42%.

At three years, 85.9% of patients treated with Lynparza remained alive and free of invasive breast cancer and second cancers versus 77.1% on placebo.

“While there have been great strides in the early treatment of breast cancer, the fear of cancer returning is still at the forefront of patients’ minds,” commented Sue Friedman, executive director, Facing Our Risk of Cancer Empowered (FORCE) and member of the OlympiA trial steering committee. “New targeted treatment approaches are needed in the adjuvant setting that can help keep cancer and that fear at bay.”

Dave Fredrickson, executive vice president, Oncology Business Unit, at AZ, said: “This is the first time that any medicine targeting a BRCA mutation has demonstrated the potential to change the course of early-stage breast cancer and offer hope for a cure. By providing a treatment which significantly reduces the risk of breast cancer returning in these high-risk patients, we hope Lynparza will set a new benchmark demonstrating sustained clinical benefit. “We are working with regulatory authorities to bring Lynparza to these patients as quickly as possible.”

Roy Baynes, senior vice president and head of Global Clinical Development, chief medical officer, MSD Research Laboratories, also noted that the data “support the importance of testing at diagnosis for BRCA1/2 mutations, which are actionable biomarkers that can help identify patients with early breast cancer who may be eligible for adjuvant treatment with Lynparza.”

An estimated 2.3 million people were diagnosed with breast cancer worldwide in 2020 and BRCA mutations are found in approximately 5% of breast cancer patients.

Reference:
https://www.pharmatimes.com/news/lynparza_shows_promise_in_preventing_cancer_recurrence_1371212

More News
ECHA Adds Five Hazardous Chemicals To PIC
News · 08/09/2023

The European Chemicals Agency (ECHA) has amended the Prior Informed Consent (PIC) Regulation, EU 64/2012, to add 27 pesticides and eight industrial chemicals into Annex I, bringing the total to 295. As a result, EU exporters are now required to notify their intentions to export them from 1 November onwards.

READ MORE
Global Custom Synthesis & Manufacturing: Escalating Demand for Specialty Chemicals Drives Growth
News · 04/09/2023

The global custom synthesis and manufacturing market was valued at US$271.33 billion in 2022. The market value is expected to reach US$474.94 billion by 2028.

READ MORE
4 key Trends Reshaping Ocean freight Industry in 2023
News · 04/04/2023

The ocean freight industry is undergoing a massive transformation, as the technology and supply chain management tools are being improved by the day, impacting ocean freight rates.

READ MORE
What do China’s data export regulations mean for its trade competitiveness?
News · 13/12/2022

In the second half of 2022, China unveiled the details of its data export regulations, providing further explanations to its existing laws and regulations on data.

READ MORE
Energy Crisis: The EU Chemical Industry Is Reaching Breaking Point
News · 11/11/2022

The current energy crisis has reached an unsustainable level for the European chemical industry. For the first time ever, the EU imports more chemicals than it exports, both in volume and value, resulting in a trade deficit of € 5.6 bn for the first half of 2022.

READ MORE
European Union proposes to add two new hazard classes to EU CLP regulation for endocrine disruptors (EDCs)
News · 17/10/2022

Endocrine Disrupting Chemicals (also referred to as hormone disruptors or EDCs) are synthetic chemicals that are not produced by the human body and that disrupt the normal functioning of humans and animals.

READ MORE
The Shipping Industry in a downward spiral
News · 03/10/2022

The shipping industry is now returning to normality and is in a downward spiral. The cost of shipping goods from China has slumped to the lowest level in more than two years as the world economy stumbles, dimming prospects for container carriers that turned in record profits during the pandemic.

READ MORE
Global Freight Situation
News · 08/09/2022

No precipitous plunge in container shipping rates, just ‘orderly’ decline.

READ MORE
3 Key Insights into the Global Food and Beverage Market
News · 02/08/2022

The global food and beverage market size is expected to grow from $5.8 trillion in 2021 to $6.4 trillion in 2022 at a growth rate of 9.7%. The food and beverage market size is expected to grow to $8.9 trillion in 2026 at a compound annual growth rate of 8.7%.

READ MORE